Kairos Pharma, LTD. (KAPA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.83
- As of
Kresmion compiles this page from KAPA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Kairos Pharma, LTD. (KAPA): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-06.
See the full KAPA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for KAPA on one page. Preview it with sample data, then open it live with a free account.
Preview the KAPA dossierActive signals for KAPA
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 26.5%, EPS $-0.06 vs $-0.0816 estimate
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 58% of KAPA (2026Q1)
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 42.6% - EPS $-0.08 vs $-0.0561 estimate
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 28.7% - EPS $-0.07 vs $-0.0544 estimate
FREE, NO ACCOUNT
Every signal on KAPA, as it fires
New filings, 13F moves and cross asset signals on KAPA land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in KAPA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 48301N104 · 2026Q2 | $119K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, KAPA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
KAPA against its peers
KAPA's return on equity of -85.9% ranks in the 68th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | KAPA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 405000 | n/a | 15 |
| Revenue YoY | n/a | -30.9% | n/a | 6 |
| Gross margin | n/a | 64.8% | n/a | 7 |
| Operating margin | n/a | -484.3% | n/a | 13 |
| Net margin | n/a | -484.6% | n/a | 13 |
| Return on equity | -85.9% | -128.5% | 68 | 16 |
| 1 year | -90.2% | -76.0% | 4 | 11 |
Peers (20): DRMA, SNGX, LNAI, XBIO, CDIO, GLMD, PULM, BGMS, LEXX, NCNA, EVGN, CLGN, AAGH, APTOF, CANF, ALZN, EMMA, CSCIF, PCSA, CELZ. Left out: XTLB (period gap), LIMN (no annual filing), ADXN (period gap), BVAXF (no annual filing), ENLV (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (KAPA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow KAPA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to KAPA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.